The first half of the session in European markets is characterized by cautious optimism among investors. The positive sentiment is fueled by the extension of the trade truce between the USA and China. This may support luxury companies in the long term, although today's session does not yet indicate this. Uncertainty persists due to upcoming peace negotiations in Alaska and unsatisfactory macroeconomic prospects for some European countries. DE40 and EU50 are losing 0.15% and 0.05% respectively before noon, while other European indices are recording gains around 0.2-0.4%.
Investor attention is focused on key macroeconomic data from the USA, which could determine the further direction of the European session. Volatility is currently observed in selected contracts based on European indices
Source: xStation
Technical Analysis - DE40
DE40 continues yesterday's declines, currently hovering around the previous day's session lows of approximately 24,080 points. On the chart, we can clearly see a forming narrowing triangle pattern, after which the market will likely set the direction for the coming days. The next technical support is at 23,983 points where the EMA-50 is located, followed by the upward trend line starting in April this year and the EMA-100. If these are breached, further declines can be expected. However, optimism on the chart is added by long and medium-term upward trend lines.
Company Information:
Sartorius (SRT.DE) - The company is seeing gains of over 3.5% after receiving a "Buy" recommendation from Jefferies, with a price target of 263 euros. This implies a predicted price increase of over 50% by analysts.
Spirax Group (SPX.UK) - The company's shares are up 16% after publishing reports boasting a growing order portfolio.
Hannover Re (HNR.DE) - The company reported an increase in net revenue in the first half of 2025, but the EBIT result was noticeably below expectations. Optimistic assurances from the company regarding further revenue growth did not convince investors, resulting in a 3% drop in shares.
K+S (SDF.DE) - The published EBITDA result missed investor expectations, falling 14% year-on-year. The share price continues the downward trend of recent weeks.
Valneva (VALN.US) - The French biotechnology company reports a 37% increase in revenue, translating to a 1.5% rise in share price. This is mainly due to strong sales of their IXiaro and Jaspect vaccines.
Daily Summary: CPI down, Markets Up
Procter & Gamble: After Earnings
"Mad Max" mode - Is Tesla in trouble?
Intel’s turnaround is showing results
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
